Comparable stake leader
Avista Healthcare Partners, L.P.
SEC ownership of RVL Pharmaceuticals plc
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001739426.
Disclosed value leader
Avista Healthcare Partners, L.P.
Comparable rows
0/13
Latest evidence
19 Oct 2023
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Avista Healthcare Partners, L.P.
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
19 Oct 2023
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001739426
- Issuer location
- Bridgewater, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of RVL Pharmaceuticals plc (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Avista Healthcare Partner...
Disclosed value leader
Avista Healthcare Partner...
Comparable rows
0/13
Latest evidence
19 Oct 2023
3/4/5
Highest disclosed value: $772,632
13 rows are not safely comparable across share classes.
Showing 1-8 of 13 holder rows.
Quick read
Avista Healthcare Partners, L.P. has the largest disclosed position value at $772.6K.
0 of 13 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Avista Healthcare Partners, L.P.'s linked filing trail.
Disclosed position value
Top 5
Avista Healthcare Partners, L.P.
$772.6K
Athyrium Opportunities IV Acquisi...
$201.3K
Altchem Ltd
$191K
Harsaul Foundation
$154.2K
Brian A. Markison
$92.9K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 13 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Avista Healthcare Partners, L.P. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$772,632
24,763,859 shares
|
— | 08 Aug 2022 |
| Athyrium Opportunities IV Acquisition 2 LP |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$201,290
6,451,612 shares
|
— | 08 Aug 2022 |
| Altchem Ltd |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$191,048
6,123,344 shares
|
— | 19 Oct 2023 |
| Harsaul Foundation |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$154,162
4,941,101 shares
|
— | 19 Oct 2023 |
| Brian A. Markison |
3/4/5
Chief Executive Officer, Director
|
—
class O/S missing
|
$92,852
2,976,020 shares
|
— | 08 Aug 2022 |
| James Schaub |
3/4/5
EVP and COO
|
—
class O/S missing
|
$16,375
524,835 shares
|
— | 18 May 2023 |
| Christopher Klein |
3/4/5
General Counsel & Secretary
|
—
class O/S missing
|
$5,634
180,573 shares
|
— | 18 May 2023 |
| Andrew J. Einhorn |
3/4/5
Chief Financial Officer
|
—
class O/S missing
|
$5,127
164,325 shares
|
— | 24 Jan 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 20 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to RVL Pharmaceuticals plc. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Avista Healthcare Partners, L.P.
Net 12M change
$0
Latest report
19 Oct 2023
Recent insider transactions for RVL Pharmaceuticals plc
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.